Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Feb 15;12(2):288.
doi: 10.3390/life12020288.

microRNAs and Inflammatory Immune Response in SARS-CoV-2 Infection: A Narrative Review

Beatrice Maranini  1 , Giovanni Ciancio  1 , Manuela Ferracin  2 , Rosario Cultrera  3 , Massimo Negrini  4 , Silvia Sabbioni  5 , Marcello Govoni  1
Affiliations
Review

microRNAs and Inflammatory Immune Response in SARS-CoV-2 Infection: A Narrative Review

Beatrice Maranini et al. Life (Basel). .

Abstract

The current SARS-CoV-2 pandemic has emerged as an international challenge with strong medical and socioeconomic impact. The spectrum of clinical manifestations of SARS-CoV-2 is wide, covering asymptomatic or mild cases up to severe and life-threatening complications. Critical courses of SARS-CoV-2 infection are thought to be driven by the so-called "cytokine storm", derived from an excessive immune response that induces the release of proinflammatory cytokines and chemokines. In recent years, non-coding RNAs (ncRNAs) emerged as potential diagnostic and therapeutic biomarkers in both inflammatory and infectious diseases. Therefore, the identification of SARS-CoV-2 miRNAs and host miRNAs is an important research topic, investigating the host-virus crosstalk in COVID-19 infection, trying to answer the pressing question of whether miRNA-based therapeutics can be employed to tackle SARS-CoV-2 complications. In this review, we aimed to directly address ncRNA role in SARS-CoV-2-immune system crosstalk upon COVID-19 infection, particularly focusing on inflammatory pathways and cytokine storm syndromes.

Keywords: COVID-19; SARS-CoV-2; cytokine storm; immune response; inflammatory response; lncRNAs; miRNAs; ncRNAs.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Jin J., Agarwala N., Kundu P., Harvey B., Zhang Y., Wallace E., Chatterjee N. Individual and community-level risk for COVID-19 mortality in the United States. Nat. Med. 2021;27:264–269. doi: 10.1038/s41591-020-01191-8. - DOI - PubMed
    1. Ramos-Casals M., Brito-Zeron P., Mariette X. Systemic and organ-specific immune-related manifestations of COVID-19. Nat. Rev. Rheumatol. 2021;17:315–332. doi: 10.1038/s41584-021-00608-z. - DOI - PMC - PubMed
    1. Cron R.Q. COVID-19 cytokine storm: Targeting the appropriate cytokine. Lancet Rheumatol. 2021;3:e236–e237. doi: 10.1016/S2665-9913(21)00011-4. - DOI - PMC - PubMed
    1. Castelli V., Cimini A., Ferri C. Cytokine Storm in COVID-19: “When You Come Out of the Storm, You Won’t Be the Same Person Who Walked in”. Front. Immunol. 2020;11:2132. doi: 10.3389/fimmu.2020.02132. - DOI - PMC - PubMed
    1. Kessel C., Vollenberg R., Masjosthusmann K., Hinze C., Wittkowski H., Debaugnies F., Nagant C., Corazza F., Vély F., Kaplanski G., et al. Discrimination of COVID-19 from inflammation-induced cytokine storm syndromes by disease-related blood biomarkers. Arthritis Rheumatol. 2021;73:1791–1799. doi: 10.1002/art.41763. - DOI - PMC - PubMed

LinkOut - more resources